Tinofend® Tinospora cordifolia Stem Extract


Heart-leaved Moonseed | Amrita | Guduchi | Giloe | Galo


Supports general immune health*

Supports exercise performance*

Supports cognitive function*


Tinospora cordifolia is a Rasayana—the category of elixirs and tonic herbs prized by the branch of Ayurvedic medicine concerned with rejuvenation and focused on promoting a youthful state of physical and mental health. In India, it is commonly called Amrita, which translates as immortality, Guduchi, which translates as that which protects the entire body, or Giloe, which means heavenly elixir [1,2]. T. cordifolia is considered to be a mental rejuvenator (Madhya Rasayana); one of its traditional uses were tonic to counter mental fatigue and improve thinking. T. cordifolia was also believed to function as an adaptogen, supporting resistance to and recovery from stress. Many of its traditional uses revolved around immunity, especially in supporting balanced immune function. T. cordifolia contains a range of active compounds including polysaccharides and bitter compounds [3–6].*



Tinofend® is backed by strong science; it is a clinically studied Tinospora cordifolia stem extract, which supports immune balance and exercise performance.

Tinofend® is a full-spectrum stem extract, which means it is designed to maintain the balance of the various constituents found in the stem. It is standardized to contain not less than 20% polysaccharides and 5% total bitters.

Created by Verdure Sciences, Inc, an award-winning leader in the research and sustainability of Ayurvedic herbs.

Tinofend® is a registered trademark of Verdure Sciences, Inc.

Tinofend® is wildcrafted, non-GMO, gluten-free, and vegan.


Because Tinospora cordifolia is an Ayurvedic Rasayana herb, we consider dosing to follow hormetic principles similar to herbal adaptogens (see Neurohacker Dosing Principles). Herbal adaptogens tend to have a hormetic zone (or range) where there’s a favorable biological response. It’s important to be in this zone. Based on studies where different doses have been given in the same study, we consider Tinofend® dosing to be somewhat akin to the Pareto Principle (i.e., 80-20 rule), because much of the benefits have occured at a lower dose. In human studies, Tinofend®, a standardized Tinospora cordifolia stem extract, has been given in doses ranging from 150 to 900 mg. Our dosage of Tinofend® will be consistent with the studied dosage range.*


Supports healthy immune function*

Supports immune balance [7,8]

Supports immune tolerance [9,10]

Supports innate immunity [5,6,8,11–22]

Supports adaptive immunity [5,6,16,17,19,23–25]

Supports myeloid differentiation of immune hematopoietic stem cells [13]

Supports healthy neutrophil and macrophage function [4–6,8,11–15,18,20–22]

Supports healthy dendritic cell function [16,17,26]

Supports healthy natural killer cell function [19]

Supports healthy T cell function [6,16,17,19,25]

Supports healthy B cell function [5,6,19,24]

Supports immune signaling [10,18–20,22,23,27,28]

Supports brain function*

Supports cognitive function [29–32]

Supports neuroprotection [33–35]

Supports healthy neuroimmune signaling [36]

Counters neural oxidative stress [33]

Supports healthy behavioral and cognitive responses to stress [37–40]

Promotes exercise performance*

Supports exercise performance [41]

Supports healthy cardiovascular response to exercise [41]

Supports healthy cortisol and testosterone levels [42]

Supports healthy muscles [43] 

Promotes healthy aging*

Supports healthy aging mechanisms [13,20,44–47]

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, cure, or prevent any disease.


[1] A. Upadhyay, K. Kumar, A. Kumar, H. Mishra, International Journal of Ayurveda Research 1 (2010) 112.
[2] N. Rawat, R. Roushan, World Journal of Pharmaceutical Research 7 (2018) 355–361.
[3] M.A. Haque, I. Jantan, S.N. Abbas Bukhari, J. Ethnopharmacol. 207 (2017) 67–85.
[4] U. Sharma, M. Bala, N. Kumar, B. Singh, R.K. Munshi, S. Bhalerao, J. Ethnopharmacol. 141 (2012) 918–926.
[5] A. Kapil, S. Sharma, J. Ethnopharmacol. 58 (1997) 89–95.
[6] I. Aranha, F. Clement, Y.P. Venkatesh, J. Ethnopharmacol. 139 (2012) 366–372.
[7] V.A. Badar, V.R. Thawani, P.T. Wakode, M.P. Shrivastava, K.J. Gharpure, L.L. Hingorani, R.M. Khiyani, J. Ethnopharmacol. 96 (2005) 445–449.
[8] M.V. Kalikar, V.R. Thawani, U.K. Varadpande, S.D. Sontakke, R.P. Singh, R.K. Khiyani, Indian J. Pharmacol. 40 (2008) 107–110.
[9] D. Gururaja, V. Hegde, J. Ayurveda Integr. Med. 10 (2019) 294–298.
[10] K.M. Sannegowda, S.H. Venkatesha, K.D. Moudgil, Int. J. Immunopathol. Pharmacol. 28 (2015) 521–531.
[11] N. Rege, R.D. Bapat, R. Koti, N.K. Desai, S. Dahanukar, Indian J. Gastroenterol. 12 (1993) 5–8.
[12] P.K. Gupta, M.G.R. Rajan, S. Kulkarni, Int. Immunopharmacol. 50 (2017) 168–177.
[13] S.M. Singh, N. Singh, P. Shrivastava, Fitoterapia 77 (2006) 1–11.
[14] M. Sengupta, G.D. Sharma, B. Chakraborty, BMC Complement. Altern. Med. 11 (2011) 102.
[15] L. Singh, S. Tyagi, M.A. Rizvi, H.C. Goel, J. Radiat. Res. 48 (2007) 305–315.
[16] V.K. Pandey, B.S. Shankar, K.B. Sainis, Int. Immunopharmacol. 14 (2012) 641–649.
[17] V.K. Pandey, P.J. Amin, B.S. Shankar, Int. Immunopharmacol. 23 (2014) 480–488.
[18] V.R. Desai, R. Ramkrishnan, G.J. Chintalwar, K.B. Sainis, Int. Immunopharmacol. 7 (2007) 1375–1386.
[19] P.K.R. Nair, S. Rodriguez, R. Ramachandran, A. Alamo, S.J. Melnick, E. Escalon, P.I. Garcia Jr, S.F. Wnuk, C. Ramachandran, Int. Immunopharmacol. 4 (2004) 1645–1659.
[20] N. Singh, S.M. Singh, P. Shrivastava, Immunopharmacol. Immunotoxicol. 26 (2004) 145–162.
[21] P. More, K. Pai, J. Ayurveda Integr. Med. 8 (2017) 88–92.
[22] P.K.R. Nair, S.J. Melnick, R. Ramachandran, E. Escalon, C. Ramachandran, Int. Immunopharmacol. 6 (2006) 1815–1824.
[23] V. Aher, A. Kumar Wahi, Iran J Pharm Res 11 (2012) 863–872.
[24] I. Aranha, Y.P. Venkatesh, J. Ayurveda Integr. Med. (2018).
[25] S.K. Latheef, K. Dhama, H.A. Samad, M.Y. Wani, M.A. Kumar, M. Palanivelu, Y.S. Malik, S.D. Singh, R. Singh, Virusdisease 28 (2017) 115–120.
[26] N. Singh, S.M. Singh, P. Shrivastava, Immunopharmacol. Immunotoxicol. 27 (2005) 1–14.
[27] P.V. Leyon, G. Kuttan, Int. Immunopharmacol. 4 (2004) 1569–1575.
[28] M. Tiwari, U.N. Dwivedi, P. Kakkar, J. Ethnopharmacol. 153 (2014) 326–337.
[29] A. Gupta, H. Raj, M.S. Karchuli, N. Upmanyu, Curr. Aging Sci. 6 (2013) 239–243.
[30] H.O. Malve, S.B. Raut, P.A. Marathe, N.N. Rege, J. Ayurveda Integr. Med. 5 (2014) 209–215.
[31] J. H., S. G., V. K., S. H., International Journal of Basic and Clinical Pharmacology (2016) 2159–2163.
[32] H.O. Malve, J. Ayurveda Integr. Med. 6 (2015) 233–240.
[33] J. Kosaraju, S. Chinni, P.D. Roy, E. Kannan, A.S. Antony, M.N.S. Kumar, Indian J. Pharmacol. 46 (2014) 176–180.
[34] A. Sharma, S. Kalotra, P. Bajaj, H. Singh, G. Kaur, Neuromolecular Med. 22 (2020) 81–99.
[35] H.D. Une, M.A. Ejaj, V.A. Tarde, Int J Pharma Res Rev 3 (2014) 28–35.
[36] H. Birla, S.N. Rai, S.S. Singh, W. Zahra, A. Rawat, N. Tiwari, R.K. Singh, A. Pathak, S.P. Singh, Neuromolecular Med. 21 (2019) 42–53.
[37] B.N.G. Jain, V.K. Jain, A. Shete, J. Adv. Pharm. Technol. Res. 1 (2010) 30–33.
[38] D. Dhingra, P.K. Goyal, Indian J. Pharm. Sci. 70 (2008) 761–767.
[39] H. Singh, T. Kaur, S. Manchanda, G. Kaur, Biogerontology 18 (2017) 601–614.
[40] R. Mishra, S. Manchanda, M. Gupta, T. Kaur, V. Saini, A. Sharma, G. Kaur, Sci. Rep. 6 (2016) 25564.
[41] B.A. Salve, R.K. Tripathi, A.U. Petare, A.A. Raut, N.N. Rege, Ayu 36 (2015) 265–270.
[42] S. Kumari, A. Mittal, R. Dabur, Steroids 114 (2016) 68–77.
[43] B. Sharma, V. Dutt, N. Kaur, A. Mittal, R. Dabur, J. Ethnopharmacol. 254 (2020) 112720.
[44] G.C. Jagetia, S.K. Rao, Biol. Pharm. Bull. 29 (2006) 460–466.
[45] A. Sharma, S.K. Saggu, R. Mishra, G. Kaur, Ann Neurosci 26 (2019) 10–20.
[46] A. Palmieri, L. Scapoli, A. Iapichino, L. Mercolini, M. Mandrone, F. Poli, A.B. Giannì, C. Baserga, M. Martinelli, Int. J. Immunopathol. Pharmacol. 33 (2019) 2058738419855567.
[47] N. Singh, S.M. Singh, Prakash, G. Singh, Immunopharmacol. Immunotoxicol. 27 (2005) 585–599.